Loading…
← CockpitCompetitor Analysis › PYC.AX PYC Therapeutics LimitedOpen in the cockpit ↗

PYC Therapeutics LimitedPYC.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Pharmaceuticals: Major

Australian clinical-stage biotech developing RNA-based therapies (antisense oligonucleotides) for inherited eye diseases and other genetic disorders.

≈ An early-stage RNA-therapeutics biotechMomentum strong 61
Mkt cap
$1.09B
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$3.79M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-33.0 pp
WACC 9.5%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · AUDA$1.74
1D+0.6%
1W-8.9%
1M-2.5%
3M-16.2%
6M+29.5%
YTD+5.2%
1Y+38.2%
ATR %6.9%
52w lowhigh40.8% off high

What PYC Therapeutics does

Australian clinical-stage biotech developing RNA-based therapies (antisense oligonucleotides) for inherited eye diseases and other genetic disorders.

Has no approved product, so money comes from raising capital and from Australian R&D tax incentive refunds, with partnership payments a possible later source.

In one line: An early-stage RNA-therapeutics biotech.

Products and services

  • Retinitis pigmentosa program
  • Usher syndrome program
  • Other RNA pipeline candidates

Customers

  • Patients with inherited retinal/genetic disease (v

Where it sits in the supply chain

  • Biotechnology
  • RNA therapeutics (antisense)
  • Rare/genetic disease drug development

What could go right

  • Positive clinical trial readouts
  • Pharma partnership/licensing deals

What could go wrong

  • Clinical trial failure risk
  • Cash burn before any product revenue

Moat: narrow (IP / patents). Proprietary RNA-targeting chemistry and patents on specific genetic targets protect pipeline candidates.

Headquarters: Perth, Australia · Founded: 2013

Named competitors

PYC Therapeutics at a glance

Size PYC Therapeutics (PYC.AX) is an Australia Health Care company (Pharmaceuticals: Major) with a market value of $1.09B, the 160th largest of 317 Australia companies the cockpit tracks. Shares closed at A$1.74 on 18 Nov 2026.

Performance Over six months the shares gained 29.5%, against -7.1% for the median peer and +1.2% for the Australia market (cap-weighted) — 2nd highest of 20 in its peer set.

Capital Return on invested capital runs 33.0 points below its cost of capital (9.5% WACC).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026PYC.AX 126Peer median 93
Six months, rebased to 100: PYC Therapeutics against the median of its 20 peers (local-currency closes).

PYC Therapeutics financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$0A$0A$0A$0A$0
Revenue growth—————
Gross profit-A$1.20M-A$1.20M-A$1.12M-A$1.07M-A$882,045
EBITDA-A$81.5M-A$81.5M-A$74.8M-A$59.4M-A$38.3M
Net income-A$43.3M-A$43.3M-A$50.3M-A$37.7M-A$22.8M
Free cash flow-A$45.1M-A$45.1M-A$52.5M-A$38.9M-A$24.9M
Capital expenditureA$531,391A$531,391A$975,397A$307,044A$491,116
Total debtn/aA$624,988A$1.02MA$1.11MA$315,487

Quarterly statements and history in the cockpit →

PYC Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%MEDCLVETO600812OMER300119237690VIYASH006280CMHC19524547BLUEJET600789BSLN002737000989PYC.AX6-month return →1-month return →
Up and to the right = strong over both horizons. PYC Therapeutics is the large dot.

PYC Therapeutics competitors and peer comparison

Head to head with its named competitors (PYC.AX vs IONS vs PRQR vs WVE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
PYC Therapeutics PYC.AX$1.09B+29%n/an/an/an/a
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a
ProQR Therapeutics PRQRn/a-23%n/an/an/an/a
Wave Life Sciences WVE$546M-55%-35%-321%2.2×n/a

How PYC Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PYC Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasurePYC.AXPeer medianRank in peer set
1-month return-2.5%-1.1%8th lowest of 21
6-month return+29.5%-7.1%2nd highest of 20
Distance from 52-week high-40.8%-25.0%4th lowest of 21
ROIC minus cost of capital-33.0 pp-0.2 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%49.6×n/an/a
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%1.5×-3.6%+4.2%
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%2.4×1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%17.3×n/an/a
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%2.3×4.9%+11.3%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%3.5×4.2%+21.7%
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%2.9×36.3%+20.4%
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%1.2×n/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%8.2×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%3.0×n/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%8.1×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%1.5×2.5%+6.5%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%3.2×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%1.7×-6.5%-7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%1.2×-0.3%+12.1%
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%

Questions

Who are PYC Therapeutics's main competitors?
Named competitors: Ionis Pharmaceuticals (IONS), ProQR Therapeutics (PRQR), Wave Life Sciences (WVE). The cockpit's measured peer set (industry) also includes MedinCell (MEDCL.PA), Vetoquinol (VETO.PA), North China Pharmaceutical (600812.SS), Omeros (OMER), Tianjin Ringpu Bio-technology (300119.SZ), ST Pharm (237690.KS).
How has PYC Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +29.5% against -7.1% for the median peer; over one year +38.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.